Gilead Sciences (GILD) Beats Q3 View By 3c; Accelerates $750 Million Buyback
More News related to GILD
- Gilead Sciences to Present at the NASDAQ OMX 23rd Investor Program
- Gilead Sciences (GILD) and Glaxo (GSK) Agree to Commercialize Viread Hep B Treatment in Five Asian Countries
- Gilead and GlaxoSmithKline Announce Agreement to Commercialize Viread(R) for Chronic Hepatitis B in Key Asian Countries
- 2010 IR Global Rankings: Invitation for Investors and Analysts Vote for Companies with the Best IR Program and for the Best IR Officer
- Gilead Sciences to Present at the Lazard Capital Markets 6TH Annual Healthcare Conference on Tuesday, November 17
More News related to Earnings
- Jo-Ann Stores (JAS) Falls As Investors Yawn at In-Line Results and Guidance
- Dynamex (DDMX) Posts Q1 EPS of $0.31, Tops by 5c
- Dynamex (DDMX) Reports Q1 EPS of $0.31, Beats by 5c
- Aeropostale (ARO) Delivers In 3Q, But Important 4Q Guidance Not Rosy Enough
- SeaChange (SEAC) Reports Solid Q3 Results; Guides Q4, FY11
Gilead Sciences (Nasdaq: GILD) reports Q3 EPS of $0.52, 3 cents better than the analyst estimate of $0.49. Revenues for the quarter were $1.37 billion, versus the consensus of $1.32 billion.
Gilead issues $750 million accelerated buyback which is part of their $3 billion buyback they announced last year.
Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life-threatening infectious diseases.
Sign up at EasyStockAlerts.com & Make Money Today!
Related Categories
EarningsStock Buybacks
Stocks Mentioned
+0.14Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
